A preliminary observational study presented at the American Academy of Neurology Annual Meeting (April 18–22, 2026) suggests GLP‑1 receptor agonists (GLP‑1 RAs) — medications such as semaglutide (Ozempic, Wegovy) prescribed primarily for weight loss or diabetes — were associated with modestly lower use of emergency and other health-care services among people with chronic migraine compared with those who started topiramate. The study has not yet been published in a peer‑reviewed journal.
Main findings
– In the year after starting treatment, 23.7% of people with chronic migraine who began a GLP‑1 RA had an emergency department visit, versus 26.4% of those who began topiramate.
– Compared with topiramate users, GLP‑1 users had roughly a 10% lower likelihood of ER visits, a 14% lower likelihood of hospitalization, and about a 13% lower likelihood of needing a nerve block or receiving a triptan prescription.
– GLP‑1 RA users were also less likely to start additional preventive migraine medications during follow‑up.
– These results describe associations in health records and do not establish that GLP‑1 RAs cause migraine improvement.
Study overview
Researchers analyzed a large health‑record database to identify patients with chronic migraine who initiated a GLP‑1 RA for other indications within a year of diagnosis and compared them with patients who started topiramate during the same timeframe. Each group included about 11,000 individuals and was matched on key characteristics to reduce confounding, but residual differences may remain.
Possible biological explanations (unproven in humans)
– Anti‑inflammatory effects within the trigeminal nociceptive system.
– Lower intracranial pressure from reduced cerebrospinal‑fluid secretion.
– Modulation of calcitonin gene‑related peptide (CGRP), a molecule centrally involved in migraine.
– Weight loss associated with GLP‑1 RAs; weight reduction has been linked with migraine improvement in some studies, though high‑quality randomized trial evidence is limited.
Important cautions
– This is observational data and can only show correlation, not causation. Patients should not use GLP‑1 RAs specifically to treat migraine outside clinical trials or established prescribing indications.
– The comparison to topiramate could reflect differences in tolerability and medication adherence for topiramate rather than a direct pharmacologic benefit of GLP‑1 drugs.
– investigators and experts call for randomized, controlled trials to test whether GLP‑1 RAs are safe and effective for migraine, especially in the populations most affected by migraine (young and middle‑aged women).
Practical migraine care reminders
The goals of migraine management are to relieve attacks and reduce future episodes. Self‑care measures include resting in a dark, quiet place, using cold packs, and staying hydrated. Common acute treatments include triptans, CGRP‑targeted therapies, over‑the‑counter analgesics (ibuprofen, aspirin, acetaminophen), and antiemetics. Preventive strategies are individualized and may include medications, lifestyle changes, and weight management when appropriate.
If you have migraine and are interested in new therapies or have questions about GLP‑1 drugs, discuss risks, benefits, and current evidence with your health‑care professional.